Pregled bibliografske jedinice broj: 1248439
Total tau in cerebrospinal fluid detects treatment responders among spinal muscular atrophy types 1–3 patients treated with nusinersen
Total tau in cerebrospinal fluid detects treatment responders among spinal muscular atrophy types 1–3 patients treated with nusinersen // CNS Neuroscience & Therapeutics (2022) doi:10.1111/cns.14051 (znanstveni, online first)
CROSBI ID: 1248439 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Total tau in cerebrospinal fluid detects treatment
responders among spinal muscular atrophy types 1–3
patients treated with nusinersen
Autori
Šimić, Goran ; Vukić, Vana ; Babić, Marija ; Banović, Maria ; Berečić, Ivana ; Španić, Ena ; Zubčić, Klara ; Golubić, Anja Tea ; Barišić Kutija, Marija ; Merkler Šorgić, Ana ; Vogrinc, Željka ; Lehman, Ivan ; Hof, Patrick R. ; Sertić, Jadranka ; Barišić, Nina
Vrsta, podvrsta
Radovi u časopisima,
znanstveni
Izvornik
CNS Neuroscience & Therapeutics (2022)
Status rada
Online first
Ključne riječi
biomarker ; nusinersen ; spinal muscular atrophy ; tau protein
Sažetak
Considering the substantial variability in treatment response across patients with spinal muscular atrophy (SMA), reliable markers for monitoring response to ther-apy and predicting treatment responders need to be identified. The study aimed to determine if measured concentrations of disease biomarkers (total tau protein, neu-rofilament light chain, and S100B protein) correlate with the duration of nusinersen treatment and with scores obtained using functional scales for the assessment of motor abilities.Methods: A total of 30 subjects with SMA treated with nusinersen between 2017 and 2021 at the Department of Pediatrics, University Hospital Centre Zagreb, Croatia, were included in this study. Cerebrospinal fluid (CSF) samples were collected by lum-bar puncture prior to intrathecal application of nusinersen. Protein concentrations in CSF samples were determined by enzyme- linked immunosorbent assay in 26 subjects. The motor functions were assessed using functional motor scales.Results: The main finding was significantly decreased total tau correlating with the number of nusinersen doses and motor improvement in the first 18–24 months of treatment (in all SMA patients and SMA type 1 patients). Neurofilament light chain and S100B were not significantly changed after administration of nusinersen. Conclusions: The measurement of total tau concentration in CSF is a reliable index for monitoring the biomarker and clinical response to nusinersen therapy in patients with SMA.
Izvorni jezik
Engleski
Znanstvena područja
Kemija, Temeljne medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb
Profili:
Jadranka Sertić
(autor)
Ena Španić
(autor)
Anja Tea Golubić
(autor)
Marija Babić
(autor)
Nina Barišić
(autor)
Goran Šimić
(autor)
Ana Merkler Šorgić
(autor)
Željka Vogrinc
(autor)
Marija Barišić Kutija
(autor)
Klara Zubčić
(autor)
Ivan Lehman
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE